title: Circulating factor VIII immune complexes in patients with type 2 acquired hemophilia A and protection from activated protein C-mediated proteolysis.
abstract: Factor VIII (FVIII) inhibitor antibodies are classified into 2 groups according to the kinetic pattern of FVIII inactivation. Type 2 antibodies are more commonly observed in patients with acquired hemophilia A and do not completely inhibit FVIII activity; in most cases, substantial levels of circulating FVIII are detected. Three type 2 autoantibodies from patients who had normal levels of FVIII antigen despite having low levels of FVIII activity were studied. The antibodies reacted exclusively with the light chain of FVIII but not with the C2 domain, and their epitopes were therefore ascribed to the regions in the A3-C1 domains. Heavy and light chains of FVIII were detected in plasma-derived immune complexes extracted by using protein G Sepharose. Direct binding assays using anhydro-activated protein C (anhydro-APC), a catalytically inactive derivative of activated protein C (APC) in which the active-site serine is converted to dehydroalanine, were used to examine the relation between immune complexes and APC. The intact FVIII, 80-kd light chain, and 72-kd light chain bound in a dose-dependent manner to anhydro-APC, with K(d) values of 580, 540, and 310 nM, respectively, whereas no appreciable binding was detected for the heavy chain. The 3 autoantibodies blocked FVIII binding to anhydro-APC by approximately 80% and consequently inhibited APC-induced FVIII proteolytic inactivation. These antibodies also bound to a synthetic peptide, His2009-Val2018, which contains the APC binding site. The findings suggest that binding of type 2 autoantibodies, recognizing residues His2009 to Val2018, protects FVIII from APC-mediated proteolysis and might contribute to the presence of FVIII immune complexes in the circulation.
authors.affiliation: Department of Pediatrics, Nara Medical University, Kashihara City, Nara, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Nogami
authors.forename: M
authors.initials: M
authors.lastname: Shima
authors.forename: J C
authors.initials: JC
authors.lastname: Giddings
authors.forename: K
authors.initials: K
authors.lastname: Hosokawa
authors.forename: M
authors.initials: M
authors.lastname: Nagata
authors.forename: S
authors.initials: S
authors.lastname: Kamisue
authors.forename: H
authors.initials: H
authors.lastname: Suzuki
authors.forename: M
authors.initials: M
authors.lastname: Shibata
authors.forename: E L
authors.initials: EL
authors.lastname: Saenko
authors.forename: I
authors.initials: I
authors.lastname: Tanaka
authors.forename: A
authors.initials: A
authors.lastname: Yoshioka
mesh_terms: D000936:Antigen-Antibody Complex / Q000097:blood*; D001323:Autoantibodies / Q000276:immunology*; D000939:Epitopes / Q000276:immunology; D015949:Factor IXa / Q000378:metabolism; D005169:Factor VIII / Q000276:immunology* / Q000378:metabolism; D006467:Hemophilia A / Q000276:immunology*; D006801:Humans; D009842:Oligopeptides / Q000276:immunology; D010743:Phospholipids / Q000378:metabolism; D011486:Protein C / Q000378:metabolism*; D014841:von Willebrand Factor / Q000378:metabolism
chemical_list: D000936:Antigen-Antibody Complex; D001323:Autoantibodies; D000939:Epitopes; D009842:Oligopeptides; D010743:Phospholipids; D011486:Protein C; D014841:von Willebrand Factor; D005169:Factor VIII; D015949:Factor IXa